149 related articles for article (PubMed ID: 17535009)
21. The pharmaceutical industry--prices and progress.
Scherer FM
N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
[No Abstract] [Full Text] [Related]
22. Operationalizing value-based pricing of medicines : a taxonomy of approaches.
Sussex J; Towse A; Devlin N
Pharmacoeconomics; 2013 Jan; 31(1):1-10. PubMed ID: 23329588
[TBL] [Abstract][Full Text] [Related]
23. [Medical problems associated with the national reference pricing system in Hungary].
Kerpel-Fronius S
Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
[TBL] [Abstract][Full Text] [Related]
24. The role of economic evaluation in the pricing and reimbursement of medicines.
Drummond M; Jönsson B; Rutten F
Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
[TBL] [Abstract][Full Text] [Related]
25. The enigma of value: in search of affordable and accessible health care.
Szucs TD; Weiss M; Klaus G
Eur J Health Econ; 2017 Jul; 18(6):667-670. PubMed ID: 27913941
[TBL] [Abstract][Full Text] [Related]
26. Pricing in the NHS.
Ellwood S
Br J Hosp Med; 1996 Sep 18-Oct 1; 56(6):299-301. PubMed ID: 8889106
[TBL] [Abstract][Full Text] [Related]
27. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
28. Implementation of Value-based Pricing for Medicines.
Jommi C; Armeni P; Costa F; Bertolani A; Otto M
Clin Ther; 2020 Jan; 42(1):15-24. PubMed ID: 31882225
[TBL] [Abstract][Full Text] [Related]
29. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
30. Comparative approaches to pharmaceutical price regulation in the European Union.
Mrazek MF
Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524
[TBL] [Abstract][Full Text] [Related]
31. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
32. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.
Lee IH; Bloor K; Hewitt C; Maynard A
J Health Serv Res Policy; 2015 Jan; 20(1):52-9. PubMed ID: 25092883
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of pharmaceutical innovation: challenges and opportunities arising from the reforms to the national health service in the United Kingdom.
St Leger S; Rowsell K; Standing V; Haycox A
Pharmacoeconomics; 1992 May; 1(5):306-11. PubMed ID: 10146995
[No Abstract] [Full Text] [Related]
34. Does drug price-regulation affect healthcare expenditures?
Ben-Aharon O; Shavit O; Magnezi R
Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
[TBL] [Abstract][Full Text] [Related]
35. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
36. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
[TBL] [Abstract][Full Text] [Related]
37. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
38. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
Ioannides-Demos LL; Ibrahim JE; McNeil JJ
Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
[TBL] [Abstract][Full Text] [Related]
39. The value of innovation under value-based pricing.
Moreno SG; Ray JA
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123192
[TBL] [Abstract][Full Text] [Related]
40. Drug Utilization and Drug Pricing in the Private Primary Healthcare System in Malaysia: An Employer Price Control Mechanism.
Zin CS; Taufek NH; Bux SH
Front Public Health; 2020; 8():551328. PubMed ID: 33365294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
